tailieunhanh - Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

The work programme 2011 is to be published in July 2010 for proposals to be selected in 2011. It aims to ensure complementarity with the previous work programme and to concentrate on specific activities within the budgetary constraints. The estimated total budget allocation for work programme 2011 is EUR 682 million (to be confirmed) drawing from the 2011 budget 1 . Section II of this document describes the topics for which project proposals can be submitted; sections III and IV describe the modalities for implementation of the different calls 2 and other actions. The estimated budget breakdown for work programme 2011. | Number 14 WEALTH Effective Health Care Comparative Effectiveness Safety and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions Although oral antidiabetic agents are used as first-line agents in patients with type 2 diabetes insulin is required in a significant number of patients at some stage during the management of diabetes to maintain optimal glycemic control. Insulin use has been suggested as a first-line therapy in patients with type 2 diabetes either as an add-on therapy to the existing noninsulin antidiabetic medications or as a replacement for noninsulin medications. According to the National Health Interview Survey 28 percent of patients with type 2 diabetes are using insulin either alone 16 percent or in combination with oral antidiabetic agents 12 percent . To mimic the release of insulin from pancreatic beta-cells in response to food intake near-physiologic insulin replacement regimens involve giving insulin at specific times in relation to meals. In addition some formulation of a longer acting insulin is prescribed to mimic the relatively constant and slow release of insulin that regulates hepatic gluconeogenesis and lipolysis. However the addition of insulin to treatment Agency for Healthcare Research and Quality Advancing Excellence in Health Care Effective Health Care Effective Health Care Program The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers health care providers and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews the program supports systematic appraisals of existing scientific evidence regarding treatments for high-priority health conditions. It also promotes and generates new scientific evidence by identifying gaps in existing scientific evidence and